President Joe Biden's administration is appealing a lower court's decision that would roll back US Food and Drug Administration actions in 2016 and 2021 to ease access to mifepristone - The abortion opponents who are seeking to convince the US Supreme Court to limit access to the abortion pill mifepristone point to three studies by Gynuity Health Projects, a New York-based women's health research group, to back up their arguments that it is unsafe despite its regulatory approval...
President Joe Biden's administration is appealing a lower court's decision that would roll back US Food and Drug Administration actions in 2016 and 2021 to ease access to mifepristone. A ruling in favour of the plaintiffs could undercut federal regulatory authority over drug safety beyond just this medication.
The FDA gave mifepristone regulatory approval in 2000. It has said that after decades of use by millions of women in the United States and around the world, mifepristone has proven "extremely safe," and that "study after study" has shown that "serious adverse events are exceedingly rare." "So it's not surprising that if they have a question or concern they may go to an emergency department as many people in America do for much of their urgent healthcare," Grossman said.
"The studies that FDA cited in 2021 show that the risk of these emergency room trips will increase without the initial in-person visit. That should've caused the FDA concern. Instead, it pressed forward with its changes, compromising the health and safety of women," Baptist added.
پاکستان تازہ ترین خبریں, پاکستان عنوانات
Similar News:آپ اس سے ملتی جلتی خبریں بھی پڑھ سکتے ہیں جو ہم نے دوسرے خبروں کے ذرائع سے جمع کی ہیں۔
ذریعہ: DunyaNews - 🏆 1. / 83 مزید پڑھ »
ذریعہ: DunyaNews - 🏆 1. / 83 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »
ذریعہ: BOLNETWORK - 🏆 9. / 63 مزید پڑھ »
ذریعہ: PTVNewsOfficial - 🏆 16. / 51 مزید پڑھ »